1
Shaw Alan, Przysiecki Craig T, Flanagan Elizabeth, Ionescu Roxana, Shi Li, Wu Yimin, Saul Allan, Miller Louis: A method for improving the immunogenicity of plasmodium antigens. Merck & Co, National Institutes Of Health, Shaw Alan, Przysiecki Craig T, Flanagan Elizabeth, Ionescu Roxana, Shi Li, Wu Yimin, Saul Allan, Miller Louis, MERCK 126 East Lincoln Avenue Rahway New Jersey 07065 0907, November 23, 2006: WO/2006/124712 (18 worldwide citation)

The present invention provides a Malaria antigen-carrier conjugate, which comprises a carrier protein and a plurality of Plasmodium antigen polypeptides. Each of the antigen polypeptides is a wild-type antigen protein of Plasmodium or a derivative of the wild-type antigen protein, and each of the an ...


2
Cooper Juan Anton, Relf Wendy Anne, Good Michael Frances, Saul Allan James: Synthetic peptides and vaccines comprising same. Queensland Inst Med Res, Commw Scient Ind Res, Univ Melbourne, Inst Medical W & E Hall, Biotech Australia, Csl, August 6, 1997: EP0787139-A1

The present invention relates generally to chimeric peptides comprising one or more protective epitopes in a conformation enabling immunological interactivity and to vaccine compositions comprising same. The present invention is particularly directed to a chimeric peptide capable of inducing protect ...


3
Smythe Jason Arthur, Anders Robin Fredric, Kemp David James, Coppel Ross Leon, Saul Allan James, Jones Graham Lloyd, Irving David Owen, Dyer Sandra Leigh, Chee David Wai Wing, Goss Neil Howard: Allelic variants of plasmodium falciparum merozoite surface antigen.. Saramane, November 27, 1991: GB2244273-A

A merozoite surface antigen of Plasmodium falciparum selected from the class characterised by: (i) having a relative molecular mass, Mr, (determined by SDS-polyacrylamide gel electrophoresis) in the range of approximately 41,000 to 53,000; and (ii) comprising multiple allelic forms of MSA2, having c ...


4
Saul Allan James, Cooper Juan Anton, Irving David Owen: Cloning and expression of a rhoptry associated protein of -i(p.falciparum).. Saramane, May 19, 1993: EP0541629-A1

A synthetic or recombinant polypeptide displaying the antigenicity of the 42 kDa rhoptry-associated protein (RAP-2) of P.falciparum or an antigenic fragment thereof, and recombinant DNA molecules, vectors and host cells for the expression thereof.


5
Saul Allan J, Cooper Juan A, Irving David O: Clonage et expression dune proteine de p. falciparum avec association rhoptry, Cloning and expression of a rhoptry associated protein of p. falciparum. Saramane, Program For Appropriate Technology In Health, RIDOUT & MAYBEE, February 20, 1992: CA2088478

A synthetic or recombinant polypeptide displaying the antigenicity of the 42 kDa rhoptry-associated protein (RAP-2) ofP.falciparum or an antigenic fragment thereof, and recombinant DNA molecules, vectors and host cells for the expression there-of.


6

7

8

9
Shaw Alan, Przysiecki Craig T, Flanagan Elizabeth, Ionescu Roxana, Shi Li, Wu Yimin, Saul Allan, Miller Louis: A method for improving the immunogenicity of plasmodium antigens. Merck & Co, Nat Inst Health, February 13, 2008: EP1885395-A2

The present invention provides a Malaria antigen-carrier conjugate, which comprises a carrier protein and a plurality of Plasmodium antigen polypeptides. Each of the antigen polypeptides is a wild-type antigen protein of Plasmodium or a derivative of the wild-type antigen protein, and each of the an ...


10